酪氨酸激酶抑制剂药物治疗肿瘤肾脏不良反应的系统评价\_附件材料

**框1　PubMed检索策略**

#1 tyrosine kinase inhibitor [Mesh terms]

#2TKI OR tyrosine kinase inhibitors OR tyrosine kinase inhibitor OR TKI OR phenylacetyl-Phe-Ser-Arg-N-(2,4-dinitrophenyl)ethylenediamine OR naquotinib OR TKIs OR ASP-8273 OR TKI cpd OR Sunitinib OR Sunitinib Malate OR Sutent OR SU 11248 OR SU011248 OR SU 011248 OR SU-011248 OR SU11248 OR SU-11248 OR Sorafenib OR BAY 43-9006 OR BAY 43 9006 OR BAY 439006 OR Sorafenib N-Oxide OR Sorafenib N Oxide OR BAY-673472 OR BAY 673472 OR BAY 545-9085 OR BAY 545 9085 OR BAY 5459085 OR BAY-545-9085 OR BAY5459085 OR Sorafenib Tosylate OR Pazopanib OR GW 786034B OR GW786034B OR GW-786034B OR GW 780604 OR GW780604 OR GW-780604 OR Votrient OR Axitinib OR AG 013736 OR AG-013736 OR Inlyta OR Cabozantinib OR XL 184 OR XL184 cpd OR XL 184 OR BMS 907351 OR BMS907351 OR BMS907351 OR Lenvatinib OR lenvatinib mesylate OR lenvatinib methanesulfonate OR Lenvima OR E-7080 mesylate OR E 7080 OR E-7080 OR ER-203492-00 OR E7080 OR lenvatinib metabolite M2 OR Vandetanib OR caprelsa OR Zactima OR ZD 6474 OR ZD6474 OR ZD-6474 OR Lestaurtinib OR SP-924 OR SPM-924 OR SP924 OR CEP-701 OR CEP 701 OR CEP701 OR KT-5555 OR KT5555 OR KT-555 OR Gefitinib OR Iressa OR ZD1839 OR ZD 1839 OR Ibrutinib OR PCI 32765 OR PCI32765 OR PCI-32765 OR dacomitinib OR anlotinib

#3 #1 OR #2

#4 Renal insufficiency [Mesh terms]

#5 Kidney Injuries OR Renal Injury OR Renal Injuries OR Kidney Insufficiency OR Kidney Insufficiencies OR Renal impairment OR Kidney Injury OR Renal Insufficiencies OR Renal Insufficiency OR Kidney Failure OR Kidney Failures OR Renal Failure OR Renal Failures OR Dideoxyadenosine OR adverse renal effect OR renal adverse event OR nephrotoxicity OR renal toxicity OR renal dysfunction OR renal dysfunction OR Nephrocalcinosis OR Hypercalciuria OR Proteinuria OR Hypertension OR electrolyte disorders OR electrolyte imbalances OR hypomagnesemia OR hypokalemia OR Hypertensive OR urine creatinine OR Creatinine OR anemia OR anaemia OR hypohemia OR eczema OR hyphemia OR diarrhoea OR blood urea nitrogen OR serum creatinine OR Serum creatine OR adverse renal event

#6 #4 OR #5

#7 randomized controlled trial [pt]

#8 controlled clinical trial [pt]

#9 randomized [tiab]

#10 placebo [tiab]

#11 drug therapy [sh]

#12 randomly [tiab]

#13 trial [tiab]

#14 groups [tiab]

#15 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14

#16 #3 AND #6 AND #15

通过数据库检索获得相关文献（*n*=2 138）\*

剔重后获得文献（*n*=1 989）

阅读文题和摘要初筛（*n*=1 989）

通过其他途径检索获得相关文献（*n*=0）

阅读全文复筛（*n*=22）

纳入定性分析的文献（*n*=19）

排除（*n*=1 967）

排除（*n*=3）：

•重复发表（*n*=2）

•无主要结局指标（*n*=1）

纳入定量合成（Meta分析）的文献（*n*=19）

**图1　文献筛选流程及结果**

\*所检索的数据库及检出文献数具体如下：VIP（*n*=11）、WanFang Data（*n*=45）、PubMed（*n*=1008）、EMbase（*n*=133)、Cochrane Library（*n*=941）